{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:55:56Z","timestamp":1781661356587,"version":"3.54.5"},"reference-count":22,"publisher":"Norwegian Medical Association","issue":"13\/14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2011,7,1]]},"DOI":"10.4045\/tidsskr.10.0053","type":"journal-article","created":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T09:09:04Z","timestamp":1309511344000},"page":"1285-8","source":"Crossref","is-referenced-by-count":1,"title":["Behandling av idiopatisk pulmonal arteriell\u00a0 hypertensjon"],"prefix":"10.4045","volume":"131","author":[{"given":"Arne K.","family":"Andreassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Gude","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Geir","family":"Solberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Ueland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 1527\u2009\u2013\u200938. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18332270&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1161\/CIRCULATIONAHA.107.188525","DOI":"10.1016\/j.jacc.2008.01.024"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216\u2009\u2013\u200923.","DOI":"10.7326\/0003-4819-107-2-216"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM et al. Survival in\u00a0patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11041398&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0140-6736(00)02714-8","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Gali\u00e8 N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and\u00a0Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT. Eur Heart J 2009; 30: 2493\u2009\u2013\u2009537. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11052583&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0140-6736(00)02844-0","DOI":"10.1016\/S0140-6736(00)02844-0"},{"key":"ref=5","unstructured":"Andreassen AK, Geiran O, Madsen S et al. Pulmonal arteriell hypertensjon behandlet med prostasyklin eller kalsiumblokade. Tidsskr Nor L\u00e6geforen 2003; 123: 3393-6. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19850214&dopt=Abstract"},{"key":"ref=6","unstructured":"Andreassen AK, Madsen S, Kjekshus J et al. Inhalasjon av en prostasyklinanalog (iloprost) ved\u00a0prim\u00e6r og sekund\u00e6r pulmonal hypertensjon. Tidsskr Nor L\u00e6geforen 2001; 121: 1220-3. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18391109&dopt=Abstract"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Sandoval J, Bauerle O, Palomar A et al. Survival in\u00a0primary pulmonary hypertension. Validation of\u00a0a\u00a0prognostic equation. Circulation 1994; 89: 1733\u2009\u2013\u200944. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17578725&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1080\/10976640601187596","DOI":"10.1161\/01.CIR.89.4.1733"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Gali\u00e8 N, Rubin Lj, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a\u00a0double-blind, randomised controlled trial. Lancet 2008; 371: 2093\u2009\u2013\u2009100.","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Machado RD, Pauciulo MW, Thomson JR et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68: 92\u2009\u2013\u2009102. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18042059&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1540-8183.2007.00294.x","DOI":"10.1086\/316947"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Humbert M, Morrell NW, Archer SL et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (suppl S): 13S-24S. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20965979&dopt=Abstract","DOI":"10.1016\/j.jacc.2004.02.029"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Sitbon O, Humbert M, Ja\u00efs X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105\u2009\u2013\u200911. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20531489&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045\/tidsskr.10.0590","DOI":"10.1161\/CIRCULATIONAHA.104.488486"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Tantini B, Manes A, Fiumana E et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100: 131\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19442885&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.jacc.2008.08.061","DOI":"10.1007\/s00395-004-0504-5"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995; 48: 890\u2009\u2013\u20096.","DOI":"10.1016\/S0026-895X(25)10547-6"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296\u2009\u2013\u2009302.","DOI":"10.1056\/NEJM199602013340504"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Wensel R, Opitz CF, Anker SD et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106: 319\u2009\u2013\u200924.","DOI":"10.1161\/01.CIR.0000022687.18568.2A"},{"key":"ref=16","unstructured":"Raymond RJ, Hinderliter AL, Willis PW et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214\u2009\u2013\u20099."},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780\u2009\u2013\u20098.","DOI":"10.1016\/S0735-1097(02)02012-0"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Torbicki A, Kurzyna M, Kuca P et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844\u2009\u2013\u20098.","DOI":"10.1161\/01.CIR.0000084544.54513.E2"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Andreassen AK, Wergeland R, Simonsen S et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006; 98: 525\u2009\u2013\u20099.","DOI":"10.1016\/j.amjcard.2006.02.061"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244\u2009\u2013\u20099.","DOI":"10.1183\/09031936.05.00054804"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Oudiz RJ, Gali\u00e8 N, Olschewski H et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: 1971\u2009\u2013\u200981.","DOI":"10.1016\/j.jacc.2009.07.033"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Gali\u00e8 N, Manes A, Negro L et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394\u2009\u2013\u2009403.","DOI":"10.1093\/eurheartj\/ehp022"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:46:35Z","timestamp":1781660795000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2011\/07\/originalartikkel\/behandling-av-idiopatisk-pulmonal-arteriell-hypertensjon"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,1]]},"references-count":22,"journal-issue":{"issue":"13\/14","published-print":{"date-parts":[[2011,7,1]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.10.0053","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,1]]}}}